Rocío García-Carbonero, MD, discusses the rationale of the FRESCO-2 trial of fruquintinib in mCRC.
Rocio Garcia-Carbonero, MD, PhD
Advertisement
Rocio Garcia-Carbonero MD, PhD is a consultant in Medical Oncology at Hospital Universitario Doce de. Octubre, where she leads the GI and NE Oncology Unit.
Articles by Rocio Garcia-Carbonero, MD, PhD
Rocío García-Carbonero, MD, discusses fruquintinib for the treatment of patients with metastatic colorectal cancer.
Rocío García-Carbonero, MD, PhD, discusses trends in colorectal cancer and other gastrointestinal malignancies, presented at the 2025 ESMO GI Cancers Congress.
Rocío García-Carbonero, MD, outlines diagnostic and molecular considerations for poorly differentiated GI neuroendocrine carcinoma.
Rocío García-Carbonero, MD, discusses a subgroup analysis of fruquintinib vs placebo in patients with refractory metastatic colorectal cancer.
Rocio Garcia-Carbonero, MD, discusses the rationale for the phase 2b VIRAGE trial in patients with metastatic pancreatic cancer.
Rocio Garcia-Carbonero, MD, PhD, Universidad de Sevilla, discusses the quality of life results from the RAISE study. The RAISE study was a phase III randomized, double-blind study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal cancer (mCRC) after first-line therapy with bevacizumab, oxaliplatin, or fluoropyrimidine.
Advertisement
Latest Updated Articles
Dr García-Carbonero on Outcomes With Fruquintinib in mCRC SubgroupsPublished: August 15th 2025 | Updated:
Dr. Garcia-Carbonero on Quality of Life Impact of FOLFIRI Plus Ramucirumab in mCRCPublished: August 7th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5